The introduction of the serine/threonine protein kinase mechanistic target of rapamycin (mTOR) inhibitors in transplantation pursued the challenge of reducing nephrotoxicity related to the use of CNI [15], so as to increase the life of the graft and to decrease the risk of cancer [16] or infections [17]. The gene discussed is MTOR; the disease is infection.